Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Eder

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Bone Marrow Transplantation|July 1, 1992
Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimensM V Seiden, A Elias, L Ayash, et al.
Blood|December 1, 1990
Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapyL Schapira, J H Antin, B J Ransil, et al.
Cancer Research|December 15, 1995
DNA topoisomerase II alpha expression is associated with alkylating agent resistanceJ P Eder, V T Chan, S W Ng, et al.
Cancer Treatment Reports|November 1, 1987
Pharmacokinetics of continuous-infusion high-dose thiotepaW D Henner, T C Shea, E A Furlong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1989
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow supportT C Shea, M Flaherty, A Elias, et al.
Cancer Research|February 15, 1991
Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinomaB A Teicher, T S Herman, J Tanaka, et al.
Cancer Chemotherapy and Pharmacology|January 5, 2002
Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignanciesC A Bunnell, J G Supko, J P Eder, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patientsJ P Eder, A D Elias, L Ayash, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2000
A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusionJ G Supko, T J Lynch, J W Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1986
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancerJ P Eder, K Antman, W Peters, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Bone Marrow Transplantation|July 1, 1992
Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimensM V Seiden, A Elias, L Ayash, et al.
Blood|December 1, 1990
Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapyL Schapira, J H Antin, B J Ransil, et al.
Cancer Research|December 15, 1995
DNA topoisomerase II alpha expression is associated with alkylating agent resistanceJ P Eder, V T Chan, S W Ng, et al.
Cancer Treatment Reports|November 1, 1987
Pharmacokinetics of continuous-infusion high-dose thiotepaW D Henner, T C Shea, E A Furlong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1989
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow supportT C Shea, M Flaherty, A Elias, et al.
Cancer Research|February 15, 1991
Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinomaB A Teicher, T S Herman, J Tanaka, et al.
Cancer Chemotherapy and Pharmacology|January 5, 2002
Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignanciesC A Bunnell, J G Supko, J P Eder, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patientsJ P Eder, A D Elias, L Ayash, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2000
A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusionJ G Supko, T J Lynch, J W Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1986
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancerJ P Eder, K Antman, W Peters, et al.
Pageof 6